文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

益生菌对重症患者呼吸机相关性肺炎发生率的影响:一项随机临床试验

Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01
一句话结论在需机械通气的重症患者中,鼠李糖乳杆菌GG未能降低VAP发生率,且益生菌相关不良事件显著增加,不支持常规使用。

该研究为在加拿大、美国、沙特阿拉伯44个ICU开展的多中心随机安慰剂对照试验,纳入2653例预计需机械通气至少72小时的成人患者,随机接受肠内鼠李糖乳杆菌GG(1×10^10 CFU)或安慰剂每日两次。20项预设次要终点亦均无显著差异。结论不支持在重症患者中使用鼠李糖乳杆菌GG。

要点

  • 20项预设次要终点(包括其他ICU获得性感染、腹泻、抗菌药物使用、死亡率、住院时间)均无显著差异。
  • 研究结论明确不支持在重症患者中使用鼠李糖乳杆菌GG预防VAP。

适用人群与场景

  • 加拿大、美国、沙特阿拉伯44个ICU中预计需机械通气至少72小时的成人患者,共2653例随机分组。

诊断标准与关键阈值

  • VAP由双人盲法中心裁定确定。
  • 原文未提及VAP的具体诊断标准或评分界值。

处置流程与药物剂量

  • 肠内给予鼠李糖乳杆菌GG 1×10^10 CFU,每日两次,在ICU内使用;中位使用天数9天(IQR 5-15天)。
  • 对照组接受安慰剂,每日两次。

红旗征与不能漏的情况

  • 益生菌组发生鼠李糖乳杆菌无菌部位感染或为非无菌部位唯一/主要病原体的事件(15例,1.1%),需警惕益生菌相关感染。

研究设计与关键结果

  • 研究类型:多中心随机安慰剂对照试验,44个ICU,2653例随机(益生菌组1321例,对照组1332例),2650例(99.9%)完成试验。
  • 人群:平均年龄59.8岁(SD 16.5),女性1063例(40.1%),平均APACHE II评分22.0(SD 7.8)。
  • 干预与对照:肠内鼠李糖乳杆菌GG 1×10^10 CFU vs 安慰剂,每日两次。
  • 次要终点:20项预设次要终点(包括其他ICU获得性感染、艰难梭菌感染、腹泻、抗菌药物使用、ICU及住院时间、死亡率)均无显著差异。

证据类型、等级与局限

  • 证据类型:多中心随机安慰剂对照试验(RCT)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:原文未提及;设计上为多中心、盲法、安慰剂对照,但仅评估单一益生菌菌株,结论不能外推至其他益生菌。

对床旁实践的改变

  • 对于预计需机械通气至少72小时的成人ICU患者,不应常规使用鼠李糖乳杆菌GG预防VAP。
  • 使用益生菌时需警惕益生菌相关感染(本研究中鼠李糖乳杆菌感染风险显著增加)。
  • 原文未提及其他益生菌菌株或制剂的适用性,结论不能外推。

指南或共识出处

  • 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT02462590。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Growing interest in microbial dysbiosis during critical illness has raised questions about the therapeutic potential of microbiome modification with probiotics. Prior randomized trials in this population suggest that probiotics reduce infection, particularly ventilator-associated pneumonia (VAP), although probiotic-associated infections have also been reported.

OBJECTIVE: To evaluate the effect of Lactobacillus rhamnosus GG on preventing VAP, additional infections, and other clinically important outcomes in the intensive care unit (ICU).

DESIGN, SETTING, AND PARTICIPANTS: Randomized placebo-controlled trial in 44 ICUs in Canada, the United States, and Saudi Arabia enrolling adults predicted to require mechanical ventilation for at least 72 hours. A total of 2653 patients were enrolled from October 2013 to March 2019 (final follow-up, October 2020).

INTERVENTIONS: Enteral L rhamnosus GG (1 × 1010 colony-forming units) (n = 1321) or placebo (n = 1332) twice daily in the ICU.

MAIN OUTCOMES AND MEASURES: The primary outcome was VAP determined by duplicate blinded central adjudication. Secondary outcomes were other ICU-acquired infections including Clostridioides difficile infection, diarrhea, antimicrobial use, ICU and hospital length of stay, and mortality.

RESULTS: Among 2653 randomized patients (mean age, 59.8 years [SD], 16.5 years), 2650 (99.9%) completed the trial (mean age, 59.8 years [SD], 16.5 years; 1063 women [40.1%.] with a mean Acute Physiology and Chronic Health Evaluation II score of 22.0 (SD, 7.8) and received the study product for a median of 9 days (IQR, 5-15 days). VAP developed among 289 of 1318 patients (21.9%) receiving probiotics vs 284 of 1332 controls (21.3%; hazard ratio [HR], 1.03 (95% CI, 0.87-1.22; P = .73, absolute difference, 0.6%, 95% CI, -2.5% to 3.7%). None of the 20 prespecified secondary outcomes, including other ICU-acquired infections, diarrhea, antimicrobial use, mortality, or length of stay showed a significant difference. Fifteen patients (1.1%) receiving probiotics vs 1 (0.1%) in the control group experienced the adverse event of L rhamnosus in a sterile site or the sole or predominant organism in a nonsterile site (odds ratio, 14.02; 95% CI, 1.79-109.58; P < .001).

CONCLUSIONS AND RELEVANCE: Among critically ill patients requiring mechanical ventilation, administration of the probiotic L rhamnosus GG compared with placebo, resulted in no significant difference in the development of ventilator-associated pneumonia. These findings do not support the use of L rhamnosus GG in critically ill patients.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02462590.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Johnstone J, Meade M, Lauzier F, et al. Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial. JAMA. 2021. PMID: 34546300. doi:10.1001/jama.2021.13355

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。